AUA Guidelines Back Aquablation for 30–150 mL Prostates with 5-Year Data
PROCEPT BioRobotics announced that the American Urological Association’s updated guidelines strengthen its recommendation for Aquablation therapy as a surgical option for men with prostate volumes of 30–80 mL and recognize its use in 80–150 mL prostates. Randomized trials show durable urinary symptom and flow rate improvements through five years.
1. Guideline Strengthening
The American Urological Association updated its management guidelines for lower urinary tract symptoms due to benign prostatic hyperplasia, elevating Aquablation therapy to a strong surgical recommendation for men with 30–80 mL prostates and recognizing its use for 80–150 mL volumes.
2. Clinical Evidence and Durability
Randomized clinical trials have demonstrated that Aquablation delivers durable improvements in urinary symptoms and flow rates through five years, showing comparable or superior results to transurethral resection of the prostate and laser enucleation.
3. Expanded Patient Population
By extending its recommendation to prostates of 80–150 mL, the guidelines broaden the eligible treatment population, potentially addressing a larger portion of the estimated 40 million men in the U.S. affected by benign prostatic hyperplasia.
4. Commercial Impact and Adoption
Stronger guideline backing and expanded eligibility are expected to accelerate Aquablation adoption in urology practices, enhancing PROCEPT BioRobotics’ market positioning and supporting potential revenue growth.